Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct078
Abstract: Background: Several studies have demonstrated the potential clinical utility of TMB as a biomarker of immune checkpoint blockade in multiple tumor types, including lung cancer. Prior analyses have been retrospective and exploratory, with varying cutoffs… read more here.
Keywords: tmb cutoff; ipi; cancer; tmb ... See more keywords